Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2811376 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY2811376 Part 1 | EXPERIMENTAL | LY2811376 (5 mg up to 500 mg); once a day or twice a day for 1 day in up to 3 periods. |
| Placebo Part 1 | PLACEBO_COMPARATOR | once a day or twice a day for 1 day in up to 3 periods. |
| LY2811376 - Part 2 low dose | EXPERIMENTAL | Single dose of LY2811376, dose determined by part 1 |
| LY2811376 - Part 2 high dose | EXPERIMENTAL | Single dose of LY2811376, dose determined by part 1 |
| Placebo Part 2 | PLACEBO_COMPARATOR | single dose |
| Name | Type | Description |
|---|---|---|
| LY2811376 | DRUG | Oral capsules |
| Placebo | DRUG | Oral capsules |
Inclusion Criteria: * Healthy men and nonchild-bearing potential women * 20 years or older * Body mass index between 18-32kg/m2 Exclusion Criteria: * Taking over-the-counter or prescription medication with the exception of vitamins or minerals or stable doses of thyroid or estrogen hormone replac...
Top 20 of 24 competitors
LY2811376 is an investigational small molecule being developed for Alzheimer's Disease. It is a Phase 1 drug candidate that was studied in a completed clinical trial in healthy subjects. The drug is not approved and remains in clinical development.
LY2811376 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The drug is an investigational small molecule intended for the treatment of Alzheimer's Disease.
LY2811376 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a safety study of single doses in healthy subjects. The drug is investigational and has not been approved for any use.
LY2811376 has been studied in one completed clinical trial, NCT00838084, titled 'A Safety Study of LY2811376 Single Doses in Healthy Subjects.' This Phase 1 trial enrolled 61 participants in the United States and was placebo-controlled, randomized, and double-blind.
LY2811376 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in healthy subjects for Alzheimer's Disease. The drug is still in clinical development and has not been approved for any indication.